From: Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody
Placebo
MAD2
MAD3
MAD4
Plasma Aβ(1-40) mean (SD) concentration (pg/mL)
Maximal % change from baseline
-27.39 (48.98)
15.92 (97.17)
39.71 (17.91)
120.71 (53.21)
24 h post final dose
13.42 (28.09)
16.99a
17.50 (9.14)
86.20 (48.06)